Biora Therapeutics announces interim results of BT-600 clinical trialThe Fly • 21 days ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Mean Plasma Tofacitinib Concentration
Following administration of a single oral dose of 5 mg and 10 mg BT-600
All pharmacokinetic endpoints were achieved, with a PK profile...
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...
Biora Therapeutics announces $6M registered direct offering and concurrent private placement...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into...
Biora Therapeutics (NASDAQ:BIOR Get Free Report) and DURECT (NASDAQ:DRRX Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the...
Related Stocks: NAS:BIOR...
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower...